0
Articles |

Pulmonary Infiltrates in Neutropenic Patients With Acute Leukemia During Chemotherapy : Outcome and Prognostic Factors

Santiago Ewig; Axel Glasmacher; Barbara Ulrich; Kai Wilhelm; Harald Schäfer; Karl-Heinz Nachtsheim
Author and Funding Information

Affiliations: From the Department of Internal Medicine, University of Bonn, Bonn, Germany,  From the Department of Radiology, University of Bonn, Bonn, Germany,  From the Institute of Medical Microbiology and Immunology, University of Bonn, Bonn, Germany

Priv-Doz Dr med Santiago Ewig, Medizinische Universitätsklinik und Poliklinik, Innere Medizin/Kardiologie und Pneumologie, Sigmund Freud Str, 25, 53105 Bonn, Germany


1998 by the American College of Chest Physicians


Chest. 1998;114(2):444-451. doi:10.1378/chest.114.2.444
Text Size: A A A
Published online

Abstract

Study objective: To determine predictors of mortality from pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy, and the significance of those factors related to the underlying malignancy and its therapy as well as of those related to the severity of the illness associated with pulmonary infiltrates.

Design: A historical cohort study.

Setting: A university teaching hospital and tertiary referral center.

Patients and methods: Overall, 53 patients with neutropenia during chemotherapy and with first episodes of pulmonary infiltrates during a 4-year period were studied. Prognostic analysis included 38 variables. Multivariate analyses were performed by logistic regression.

Results: The survival rate from pneumonia was 57% (30/53). The following eight parameters were significantly associated with death in univariate analysis: comorbidity present; development of "late" pulmonary infiltrates (≥14 days after hospital admission); heart rate ≥100 beats/min; a ratio heart rate/systolic blood pressure (HR/SBP) ≥1.2; urea nitrogen >7 mmol/L; radiographic score ≥3; neutropenia <1.0x109/L at the treatment end point; and failed complete remission. In a multivariate model including only parameters available at diagnosis of pulmonary infiltrates, the presence of a ratio HR/SBP ≥1.2 and of a radiographic score ≥3 remained independently associated with death. In a second model also including the evolutionary parameter neutropenia ≤1.0x109/L at the treatment end point, both parameters remained significant together with neutropenia <1.0x109/L at the treatment end point. The presence of a ratio HR/SBP ≥1.2 was a strong marker of early death.

Conclusion: Both therapy- and malignancy-associated neutropenia as well as the severity of illness associated with pulmonary infiltrates are independent prognostic factors. Patients with a ratio HR/SBP ≥1.2 at diagnosis of pulmonary infiltrates suffer from potentially reversible acute illness, are at risk for early death and, therefore, may be appropriate candidates for treatment in an ICU.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543